GlassScriptPhysician profile
Donald Everett Schmechel
NPI 1255415139
$2,723.67
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $360 · 2021: $224 · 2022: $87.76 · 2024: $33.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $400.48 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $210.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $185.95 | 2019-2020 | |
| Genentech USA, INC. | $160.09 | 2019-2020 | |
| Ge Healthcare | $151.10 | 2019 | |
| Emd Serono, INC. | $141.83 | 2019 | |
| Mallinckrodt Enterprises LLC | $139.68 | 2019 | |
| Amgen INC. | $135.87 | 2019-2021 | |
| Genzyme Corporation | $130.63 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $116.71 | 2019-2021 | |
| Ucb, INC. | $100.74 | 2019-2024 | Briviact |
| Shire North American Group INC | $94.78 | 2019 | |
| Biogen, INC. | $80.76 | 2019-2021 | |
| Eisai INC. | $75.97 | 2019-2021 | |
| Acorda Therapeutics, INC | $73.19 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $44.36 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $36.84 | 2019 | |
| Csl Behring | $35.80 | 2019 | |
| Upsher-Smith Laboratories LLC | $35.40 | 2019 | |
| Mdd US Operations, LLC | $34.05 | 2019-2020 | |
| Sk Life Science, INC. | $33.88 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $33.10 | 2019 | |
| Lilly USA, LLC | $32.25 | 2021-2022 | |
| Lundbeck LLC | $31.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.02 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $28.00 | 2019 | |
| Bausch Health US, LLC | $24.20 | 2020 | |
| Mallinckrodt Hospital Products INC. | $20.38 | 2020 | |
| Abbvie INC. | $16.13 | 2024 | |
| Akcea Therapeutics, INC. | $15.07 | 2019 | |
| Celgene Corporation | $15.05 | 2021 | |
| Grt US Holding, INC. | $13.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.89 | 2019 | |
| Assertio Therapeutics, INC. | $11.99 | 2019 | |
| Kyowa Kirin, INC. | $11.62 | 2019 | |
| Medtronic USA, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Schmechel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.